hero section gradient
12 handpicked stocks

Poland's Artillery Ambition

Poland is investing $663 million to dramatically increase production of artillery shells, creating ripple effects across the defense industry. These carefully selected stocks represent companies throughout the supply chain poised to benefit from this strategic shift in defense spending.

Author avatar

Han Tan | Market Analyst

Published on July 1

Your Basket's Financial Footprint

Summary and investor key takeaways for the basket 'Poland's Artillery Ambition' based on provided market capitalisation breakdown.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering more stability and closer correlation with broad-market moves.
  • Suitable as a core holding for diversified portfolios, not a short-term speculative position.
  • Expect gradual, long-term appreciation rather than rapid, explosive short-term gains.
Total Market Cap
  • GD: $91.64B

  • RTX: $232.01B

  • NOC: $85.54B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Poland's massive investment to quintuple artillery shell production signals a broader NATO rearmament trend in response to the Ukraine conflict. This creates long-term growth opportunities across the defense supply chain, from major contractors to specialized component manufacturers.

2

What You Need to Know

This collection offers exposure to a specific geopolitical trend reshaping defense priorities. The stocks represent the full artillery supply chain – from raw materials and components to complete systems and targeting technologies – spanning both European and US markets.

3

Why These Stocks

These companies were selected for their direct connection to artillery production and the broader defense modernization cycle. They include prime contractors producing complete systems, specialized manufacturers of key components, and suppliers of critical materials needed for increased production.

Why You'll Want to Watch These Stocks

🛡️

Defense Budgets Are Booming

NATO countries are rapidly increasing military spending after years of underinvestment. Poland's $663 million artillery initiative is just one example of this larger, long-term trend.

🏭

Supply Chain Shortages Create Opportunity

The defense industry is scrambling to increase production capacity after decades of consolidation. Companies that can deliver critical components and materials are positioned for significant growth.

🌍

This Goes Beyond Poland

This investment theme captures the ripple effects across Europe and the US as allies coordinate to strengthen NATO's eastern flank. The artillery focus offers unique exposure to a specific, high-demand segment.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions